ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2348

Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension

Diamant Thaçi1, Luis Puig2, Joseph F. Merola3, Denis Jullien4, Antonio Costanzo5, Maggie Wang6, Delphine Deherder7, José M. López Pinto8 and Mark Lebwohl9, 1Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, 2Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 3UT Southwestern Medical Center, Dallas, TX, 4Department of Dermatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France, 5Department of Dermatology, Humanitas Clinical and Research Centre, IRCCS, Rozzano, Milan, Italy, 6UCB Pharma, Morrisville, NC, 7UCB Pharma, Braine-l'Alleud, Belgium, 8UCB Pharma, Madrid, Spain, 9Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

Meeting: ACR Convergence 2024

Keywords: Biologicals, clinical trial, Dermatology, immunology, skin

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinical improvements through Week 152, with no unexpected safety findings, were previously reported with bimekizumab (BKZ) in the BE SURE phase 3 trial and BE BRIGHT open-label extension.1,2 Here, we evaluate long-term efficacy of BKZ, as measured by complete (100% improvement from baseline in Psoriasis Area and Severity Index [PASI 100]) or near-complete skin clearance (PASI 90), in addition to safety of BKZ, through 4 years of treatment.

Methods: In BE SURE (NCT03412747), patients with moderate to severe plaque psoriasis were randomized 1:1:1 to either BKZ 320 mg every 4 weeks (Q4W) to Week 16 then Q8W to Week 56 (BKZ Q4W/Q8W), BKZ Q4W to Week 56 (Q4W/Q4W), or adalimumab (ADA) 40 mg Q2W to Week 24 then BKZ Q4W to Week 56 (ADA/BKZ).1

At Week 56, patients could enroll in BE BRIGHT (NCT03598790) to receive open-label BKZ Q4W or Q8W;3 all received BKZ Q8W from Week 104 or next scheduled visit.

Efficacy data are reported through Week 200 by initial randomization group. Patients discontinuing due to lack of efficacy/treatment-related adverse events were considered non-responders; multiple imputation was used for other missing data (modified non‑responder imputation).

Treatment-emergent adverse events (TEAEs) occurring whilst receiving BKZ (incidence/100 patient-years [PY]) are reported through Weeks 0–200.

Results: In BE SURE, 478 patients were randomized to BKZ Q4W/Q8W (N=161), BKZ Q4W/Q4W (N=158), and ADA/BKZ (N=159).1 At Week 200, PASI 90 was achieved by 83.2% of BKZ Q4W/Q8W-randomized, 82.4% BKZ Q4W/Q4W-randomized, and 87.6% ADA/BKZ-randomized patients. PASI 100 was achieved by 58.5%, 61.9%, and 69.5%, respectively.

Week 0–200 serious TEAE rate with BKZ was low (4.9/100 PY). Five deaths occurred (zero treatment-related). The most common TEAEs were: nasopharyngitis (12.3/100 PY), oral candidiasis (8.3/100 PY), and upper respiratory tract infection (6.0/100 PY). Most (99.2%) oral candidiasis events were mild or moderate; none led to discontinuation.

Conclusion: Through 4 years, clinical improvements with BKZ were maintained and BKZ was well-tolerated with no unexpected safety findings.1,2

References: 1. Thaçi D. Br J Dermatol 2023;188:22–31; 2. Thaçi D. Presented at EADV 2022, P1572; 3. Strober B. Br J Dermatol 2023;188:749–59.

Previously presented at AAD 2024. 


Disclosures: D. Thaçi: AbbVie, 1, 2, 5, 12, Investigator, Almirall, 1, 2, 12, Investigator, Amgen, 1, 2, 12, Investigator, Boehringer Ingelheim, 1, 2, 12, Investigator, Bristol Myers Squibb, 1, 2, 12, Investigator, Celltrion, 1, 2, 12, Investigator, Eli Lilly, 1, 2, 12, Investigator, Galapagos, 1, 2, 12, Investigator, Galderma, 1, 2, 12, Investigator, Janssen-Cilag, 1, 2, 12, Investigator, Kyowa Kirin, 1, 2, 12, Investigator, LEO Pharma, 1, 2, 5, 12, Investigator, Novartis, 1, 2, 5, 12, Investigator, Pfizer, 1, 2, 12, Investigator, Regeneron, 1, 2, 12, Investigator, Samsung, 1, 2, 12, Investigator, Sandoz, 1, 2, 12, Investigator, Sanofi, 1, 2, 12, Investigator, Target-Solution, 1, 2, 12, Investigator, UCB Pharma, 1, 2, 12, Investigator; L. Puig: AbbVie, 2, 5, 6, Almirall, 2, 5, 6, Amgen, 2, 5, 6, Baxalta, 2, 5, 6, Biogen, 2, 5, 6, Boehringer Ingelheim, 2, 5, 6, Bristol Myers Squibb, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 2, 5, 6, Gebro, 2, 5, 6, Janssen, 2, 5, 6, JS BIOCAD, 2, 5, 6, LEO Pharma, 2, 5, 6, Merck-Serono, 2, 5, 6, MSD, 2, 5, 6, Mylan, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Regeneron, 2, 5, 6, Roche, 2, 5, 6, Samsung-Bioepis, 2, 5, 6, Sandoz, 2, 5, 6, Sanofi-Genzyme, 2, 5, 6, UCB, 2, 5, 6; J. Merola: AbbVie, 2, 12, Investigator, Amgen, 2, 12, Investigator, Biogen, 2, 12, Investigator, Bristol Myers Squibb, 2, 12, Investigator, Dermavant, 2, 12, Investigator, Janssen, 2, 12, Investigator, LEO Pharma, 2, 12, Investigator, Lilly, 2, 12, Investigator, Novartis, 2, 12, Investigator, Pfizer, 2, 12, Investigator, Regeneron, 2, 12, Investigator, Sanofi, 2, 12, Investigator, Sun Pharma, 2, 12, Investigator, UCB, 2, 12, Investigator; D. Jullien: AbbVie, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, Almirall, 2, 4, Amgen, 2, 4, 12, Travel/accommodations expenses covered or reimbursed, Biogen, 2, 4, 12, Travel/accommodations expenses covered or reimbursed, Boehringer Ingelheim, 2, 4, Bristol Myers Squibb, 2, 4, Celgene, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, Eli Lilly, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, Fresenius Kabi, 2, 4, 12, Travel/accommodations expenses covered or reimbursed, Janssen, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, LEO Pharma, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, MEDAC, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, MSD, 2, 4, 12, Travel/accommodations expenses covered or reimbursed, Novartis, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, Pfizer, 2, 4, 6, 12, Travel/accommodations expenses covered or reimbursed, Sanofi, 2, 4, 12, Travel/accommodations expenses covered or reimbursed, UCB Pharma, 2, 4, 12, Travel/accommodations expenses covered or reimbursed; A. Costanzo: AbbVie, 1, 6, 12, Investigator, Almirall, 1, 6, 12, Investigator, Amgen, 1, 6, 12, Investigator, Boehringer Ingelheim, 1, 6, 12, Investigator, Celgene, 1, 6, 12, Investigator, Eli Lilly, 1, 6, 12, Investigator, Galderma, 1, 6, 12, Investigator, Janssen, 1, 6, 12, Investigator, LEO Pharma, 1, 6, 12, Investigator, Novartis, 1, 6, 12, Investigator, Pfizer, 1, 6, 12, Investigator, Regeneron, 1, 6, 12, Investigator, Sandoz, 1, 6, 12, Investigator, Sanofi, 1, 6, 12, Investigator, UCB Pharma, 1, 6, 12, Investigator; M. Wang: UCB Pharma, 3, 12, Shareholder; D. Deherder: UCB Pharma, 3, 12, Shareholder; J. López Pinto: UCB Pharma, 3, 12, Shareholder; M. Lebwohl: AbbVie, 5, Almirall, 2, AltruBio Inc., 2, Amgen, 5, AnaptysBio, 2, Arcutis, 2, 5, AstraZeneca, 2, Avotres, 2, 5, Boehringer Ingelheim, 2, 5, Brickell Biotech, 2, Bristol Myers Squibb, 2, Cara Therapeutics, 5, Castle Biosciences, 2, Celltrion, 2, CorEvitas, 2, Dermavant Sciences, 2, 5, Eli Lilly, 5, EPI, 2, Evommune Inc., 2, Facilitation of International Dermatology Education, 2, Forte Biosciences, 2, Foundation for Research and Education in Dermatology, 2, Galderma, 2, Genentech, 2, Incyte, 2, 5, Inozyme, 5, Janssen, 5, LEO Pharma, 2, LLC, 5, Meiji Seika Pharma, 2, Mindera, 2, Mount Sinai, 3, Ortho Dermatologics, 5, Pfizer, 2, Sanofi-Regeneron, 5, Seanergy, 2, Strata, 2, Trevi, 2, UCB Pharma, 5, Verrica, 2.

To cite this abstract in AMA style:

Thaçi D, Puig L, Merola J, Jullien D, Costanzo A, Wang M, Deherder D, López Pinto J, Lebwohl M. Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/bimekizumab-efficacy-and-safety-through-4-years-in-moderate-to-severe-plaque-psoriasis-long-term-results-from-a-phase-3-study-and-open-label-extension/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bimekizumab-efficacy-and-safety-through-4-years-in-moderate-to-severe-plaque-psoriasis-long-term-results-from-a-phase-3-study-and-open-label-extension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology